A citation-based method for searching scientific literature

Xiao-Yang Chen, Aye Aye Thike, Valerie Cui Yun Koh, Nur Diyana Md Nasir, Boon Huat Bay, Puay Hoon Tan. Virchows Arch 2021
Times Cited: 6







List of co-cited articles
37 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Higher densities of tumour-infiltrating lymphocytes and CD4+ T cells predict recurrence and progression of ductal carcinoma in situ of the breast.
Aye Aye Thike, Xiaoyang Chen, Valerie Cui Yun Koh, Nur Diyana Binte Md Nasir, Joe P S Yeong, Boon Huat Bay, Puay Hoon Tan. Histopathology 2020
17
83

Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Milim Kim, Yul Ri Chung, Hyun Jeong Kim, Ji Won Woo, Soomin Ahn, So Yeon Park. Breast Cancer Res 2020
24
66

Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.
Michael S Toss, I Miligy, Abdubaqi Al-Kawaz, Mansour Alsleem, Hazem Khout, Padmashree C Rida, Ritu Aneja, Andrew R Green, Ian O Ellis, Emad A Rakha. Mod Pathol 2018
46
66

The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.
G Pruneri, M Lazzeroni, V Bagnardi, G B Tiburzio, N Rotmensz, A DeCensi, A Guerrieri-Gonzaga, A Vingiani, G Curigliano, S Zurrida,[...]. Ann Oncol 2017
59
66

Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
Michael J Campbell, Frederick Baehner, Tess O'Meara, Ekene Ojukwu, Booyeon Han, Rita Mukhtar, Vickram Tandon, Max Endicott, Zelos Zhu, Jasmine Wong,[...]. Breast Cancer Res Treat 2017
69
66

The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
Michael S Toss, Asima Abidi, Dorothea Lesche, Chitra Joseph, Sakshi Mahale, Hugo Saunders, Tanjina Kader, Islam M Miligy, Andrew R Green, Kylie L Gorringe,[...]. Br J Cancer 2020
17
66

Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence.
Xiao-Yang Chen, Aye Aye Thike, Nur Diyana Md Nasir, Valerie Cui Yun Koh, Boon Huat Bay, Puay Hoon Tan. Virchows Arch 2020
10
66

Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
Marie Colombe Agahozo, Mieke R van Bockstal, Floris H Groenendijk, Thierry P P van den Bosch, Pieter J Westenend, Carolien H M van Deurzen. Mod Pathol 2020
11
50

Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
Xiao-Yang Chen, Joe Yeong, Aye Aye Thike, Boon Huat Bay, Puay Hoon Tan. Breast Cancer Res Treat 2019
23
50

Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.
Lotte E Elshof, Michael Schaapveld, Marjanka K Schmidt, Emiel J Rutgers, Flora E van Leeuwen, Jelle Wesseling. Breast Cancer Res Treat 2016
39
50

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.
Carlos R Gil Del Alcazar, Sung Jin Huh, Muhammad B Ekram, Anne Trinh, Lin L Liu, Francisco Beca, Xiaoyuan Zi, Minsuk Kwak, Helga Bergholtz, Ying Su,[...]. Cancer Discov 2017
124
50

Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).
Farbod Darvishian, Ugur Ozerdem, Sylvia Adams, Jennifer Chun, Elizabeth Pirraglia, Elianna Kaplowitz, Amber Guth, Deborah Axelrod, Richard Shapiro, Alison Price,[...]. Ann Surg Oncol 2019
14
50

Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features.
Shona Hendry, Jia-Min B Pang, David J Byrne, Sunil R Lakhani, Margaret C Cummings, Ian G Campbell, G Bruce Mann, Kylie L Gorringe, Stephen B Fox. Clin Cancer Res 2017
45
50

CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous "healing" in HER2-positive ductal carcinoma in situ.
Michi Morita, Rin Yamaguchi, Maki Tanaka, Gary M Tse, Miki Yamaguchi, Naoki Kanomata, Yoshiki Naito, Jun Akiba, Satoshi Hattori, Shigeki Minami,[...]. Cancer Med 2016
23
50

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.
Esther H Lips, Tapsi Kumar, Anargyros Megalios, Lindy L Visser, Michael Sheinman, Angelo Fortunato, Vandna Shah, Marlous Hoogstraat, Emi Sei, Diego Mallo,[...]. Nat Genet 2022
5
60

The immune microenvironment of breast ductal carcinoma in situ.
Elizabeth Thompson, Janis M Taube, Hillary Elwood, Rajni Sharma, Alan Meeker, Hind Nassar Warzecha, Pedram Argani, Ashley Cimino-Mathews, Leisha A Emens. Mod Pathol 2016
95
33

Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ.
Victoria Sopik, Ping Sun, Steven A Narod. Breast Cancer Res Treat 2018
42
33

Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
Marie Beguinot, Marie-Melanie Dauplat, Fabrice Kwiatkowski, Guillaume Lebouedec, Lucie Tixier, Christophe Pomel, Frederique Penault-Llorca, Nina Radosevic-Robin. BMC Cancer 2018
31
33

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, S Wienert, G Van den Eynden, F L Baehner, F Penault-Llorca,[...]. Ann Oncol 2015
33

DCIS with Microinvasion: Is It In Situ or Invasive Disease?
Cosette D Champion, Yi Ren, Samantha M Thomas, Oluwadamilola M Fayanju, Laura H Rosenberger, Rachel A Greenup, Carolyn S Menendez, E Shelley Hwang, Jennifer K Plichta. Ann Surg Oncol 2019
21
33

Immune Escape during Breast Tumor Progression.
Carlos R Gil Del Alcazar, Maša Alečković, Kornelia Polyak. Cancer Immunol Res 2020
40
33

A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.
Martin C Abba, Ting Gong, Yue Lu, Jaeho Lee, Yi Zhong, Ezequiel Lacunza, Matias Butti, Yoko Takata, Sally Gaddis, Jianjun Shen,[...]. Cancer Res 2015
87
33

The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ.
Michaela Semeraro, Julien Adam, Gautier Stoll, Emilie Louvet, Kariman Chaba, Vichnou Poirier-Colame, Allan Sauvat, Laura Senovilla, Erika Vacchelli, Norma Bloy,[...]. Oncoimmunology 2016
47
33

Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.
Michael S Toss, Islam M Miligy, Kylie L Gorringe, Mohammed A Aleskandarany, Abdulbaqi Alkawaz, Karuna Mittal, Ritu Aneja, Ian O Ellis, Andrew R Green, Emad A Rakha. Mod Pathol 2019
17
33

Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.
Islam Miligy, Priya Mohan, Ahmed Gaber, Mohammed A Aleskandarany, Christopher C Nolan, Maria Diez-Rodriguez, Abhik Mukherjee, Caroline Chapman, Ian O Ellis, Andrew R Green,[...]. Histopathology 2017
40
33

Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent.
Marie Colombe Agahozo, Pieter J Westenend, Mieke R van Bockstal, Tim Hansum, Jenny Giang, Sanneke E Matlung, Carolien H M van Deurzen. Mod Pathol 2020
8
33

Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System.
Anne Trinh, Carlos R Gil Del Alcazar, Sachet A Shukla, Koei Chin, Young Hwan Chang, Guillaume Thibault, Jennifer Eng, Bojana Jovanović, C Marcelo Aldaz, So Yeon Park,[...]. Mol Cancer Res 2021
10
33


Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing.
Anna K Casasent, Aislyn Schalck, Ruli Gao, Emi Sei, Annalyssa Long, William Pangburn, Tod Casasent, Funda Meric-Bernstam, Mary E Edgerton, Nicholas E Navin. Cell 2018
205
33

Cancer Outcomes in DCIS Patients Without Locoregional Treatment.
Marc D Ryser, Donald L Weaver, Fengmin Zhao, Mathias Worni, Lars J Grimm, Roman Gulati, Ruth Etzioni, Terry Hyslop, Sandra J Lee, E Shelley Hwang. J Natl Cancer Inst 2019
43
33

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Karla Kerlikowske, Annette M Molinaro, Mona L Gauthier, Hal K Berman, Fred Waldman, James Bennington, Henry Sanchez, Cynthia Jimenez, Kim Stewart, Karen Chew,[...]. J Natl Cancer Inst 2010
239
33

Unmasking the immune microecology of ductal carcinoma in situ with deep learning.
Priya Lakshmi Narayanan, Shan E Ahmed Raza, Allison H Hall, Jeffrey R Marks, Lorraine King, Robert B West, Lucia Hernandez, Naomi Guppy, Mitch Dowsett, Barry Gusterson,[...]. NPJ Breast Cancer 2021
10
33

Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ.
Mathilde M M Almekinders, Michael Schaapveld, Bram Thijssen, Lindy L Visser, Tycho Bismeijer, Joyce Sanders, Edoardo Isnaldi, Ingrid Hofland, Marjolijn Mertz, Lodewyk F A Wessels,[...]. NPJ Breast Cancer 2021
4
50

Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ.
Alberto Farolfi, Elisabetta Petracci, Luigi Serra, Alessandra Ravaioli, Sara Bravaccini, Sara Ravaioli, Maria Maddalena Tumedei, Paola Ulivi, Matteo Canale, Maurizio Puccetti,[...]. Front Oncol 2020
8
33

Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ.
Lotte E Elshof, Marjanka K Schmidt, Emiel J Th Rutgers, Flora E van Leeuwen, Jelle Wesseling, Michael Schaapveld. Ann Surg 2018
40
33

Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project.
Abeer M Shaaban, Bridget Hilton, Karen Clements, Elena Provenzano, Shan Cheung, Matthew G Wallis, Elinor Sawyer, Jeremy S Thomas, Andrew M Hanby, Sarah E Pinder,[...]. Br J Cancer 2021
15
33

Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.
Alastair M Thompson, Karen Clements, Shan Cheung, Sarah E Pinder, Gill Lawrence, Elinor Sawyer, Olive Kearins, Graham R Ball, Ian Tomlinson, Andrew Hanby,[...]. Eur J Cancer 2018
38
33

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Barbara I Heppner, Karsten E Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto,[...]. Lancet Oncol 2018
832
16


Destructive impact of T-lymphocytes, NK and Mast cells on basal cell layers: implications for tumor invasion.
Hongyan Yuan, Yi-Hsuan Hsiao, Yiyu Zhang, Jinlian Wang, Chao Yin, Rong Shen, Yiping Su. BMC Cancer 2013
19
16

Immunotherapy in Breast Cancer: When, How, and What Challenges?
Beatriz Henriques, Fernando Mendes, Diana Martins. Biomedicines 2021
12
16

Racial disparities in risk of second breast tumors after ductal carcinoma in situ.
Ying Liu, Graham A Colditz, Sarah Gehlert, Melody Goodman. Breast Cancer Res Treat 2014
16
16

Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers.
Peter Savas, Roberto Salgado, Sherene Loi. Breast Cancer Res Treat 2021
5
20

Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.
Amrendra Kumar, Reese Watkins, Anna E Vilgelm. Front Immunol 2021
18
16

The 2019 World Health Organization classification of tumours of the breast.
Puay Hoon Tan, Ian Ellis, Kimberly Allison, Edi Brogi, Stephen B Fox, Sunil Lakhani, Alexander J Lazar, Elizabeth A Morris, Aysegul Sahin, Roberto Salgado,[...]. Histopathology 2020
173
16


Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer.
Armando E Giuliano, Stephen B Edge, Gabriel N Hortobagyi. Ann Surg Oncol 2018
218
16

Breast Cancer Immunotherapy: Facts and Hopes.
Leisha A Emens. Clin Cancer Res 2018
323
16

The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
Paula I Gonzalez-Ericsson, Elisabeth S Stovgaard, Luz F Sua, Emily Reisenbichler, Zuzana Kos, Jodi M Carter, Stefan Michiels, John Le Quesne, Torsten O Nielsen, Anne-Vibeke Laenkholm,[...]. J Pathol 2020
86
16

Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ.
Fei-Fei Xu, Sai-Fang Zheng, Cheng Xu, Gang Cai, Shu-Bei Wang, Wei-Xiang Qi, Chao-Fu Wang, Jia-Yi Chen, Cao Lu. Oncoimmunology 2021
3
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.